# CPIX — Cumberland Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CPIX  
**Sources:** 18  
**Published:** 2026-10-22  
**Canonical:** https://app.k3vl4r.com/research/deep-research-cpix-cumberland-pharmaceuticals-inc-catalysts-narrative-8572

---

## Company Snapshot

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a Nashville, Tennessee–based specialty pharmaceutical company, founded in 1999 and IPO'd in 2009 [[4]](https://seekingalpha.com/article/4936335-cumberland-pharma-pivot-into-drug-development-creates-risk-and-opportunity), [[16]](https://www.marketbeat.com/stocks/NASDAQ/CPIX/). As of Oct 21, 2026, it trades near ~$8.17 with a market capitalization of roughly $122M, classifying it as a small-cap [[14]](https://finance.yahoo.com/quote/CPIX/), [[15]](https://stockanalysis.com/stocks/cpix/), [[16]](https://www.marketbeat.com/stocks/NASDAQ/CPIX/). Historically focused on branded acute-care/gastroenterology products (e.g., Caldolor, Vaprisol, Kristalose, Sancuso, Acetadote), the company has pivoted to a **development-stage biopharmaceutical model** centered on its lead candidate **ifetroban** after selling its commercial business [[3]](https://pennystocksunited.com/cpix-stock), [[8]](https://www.nasdaq.com/press-release/cumberland-pharmaceuticals-reports-company-update-q2-2026-financial-results-2026-08), [[15]](https://stockanalysis.com/stocks/cpix/), [[16]](https://www.marketbeat.com/stocks/NASDAQ/CPIX/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-cpix-cumberland-pharmaceuticals-inc-catalysts-narrative-8572 (free to sign up)._